Company Overview of Cerecor, Inc.
Cerecor, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of prescription pharmaceuticals. The company focuses on human brain and nervous system. Its products include translational medicines, products for cough, and inhibitors for schizophrenia. The company was incorporated in 2011 and is based in Baltimore, Maryland.
2400 Boston Street
Baltimore, MD 21224
Founded in 2011
Key Executives for Cerecor, Inc.
Founder and Chairman of Scientific Advisory Board
Founder and Member of Scientific Advisory Board
Compensation as of Fiscal Year 2013.
Cerecor, Inc. Key Developments
Cerecor, Inc. Presents at 16th Annual BIO CEO & Investor Conference 2014, Feb-10-2014 10:30 AM
Dec 19 13
Cerecor, Inc. Presents at 16th Annual BIO CEO & Investor Conference 2014, Feb-10-2014 10:30 AM. Venue: The Waldorf-Astoria Hotel, Conrad Room, New York, New York, United States. Speakers: Blake M. Paterson, Co-Founder, Chief Executive Officer and Director.
Cerecor Inc. Receives Fast Track Designation for CERC-301 for the Treatment of Major Depressive Disorder
Nov 25 13
Cerecor Inc. announced that the U.S. Food and Drug Administration has granted Fast Track designation to the company's lead clinical product candidate, CERC-301, for major depressive disorder (MDD). CERC-301 is a once daily, oral, adjunctive, selective NMDA receptor subunit 2B (NR2B) antagonist with the potential to be the first in a new class of rapidly acting antidepressants. The FDA's Fast Track Drug Development Program is designed to facilitate the clinical development and expedite the review of drugs intended to treat a serious or life-threatening condition which demonstrate the potential to address an unmet medical need. Cerecor recently announced the initiation of a Phase 2 clinical study of CERC-301 as an adjunctive treatment for subjects with MDD who have not adequately responded to their current therapy and report recent suicidal ideation.
Cerecor Inc. Receives IND Clearance from the United Stated Food and Drug Agency to Conduct Clinical Trial for its Investigational Product Candidate CERC-301
Nov 8 13
Cerecor Inc. announced it has received IND clearance from the United Stated Food and Drug Agency to conduct a clinical trial for its investigational product candidate CERC-301. The Company has initiated a Phase 2 study of CERC-301, an oral, selective NMDA receptor subunit 2B (NR2B) antagonist for the adjunctive treatment of subjects with major depressive disorder (MDD) who have not adequately responded to their current therapy and report recent suicidal ideation. In a pilot study in five patients with treatment-resistant depression (TRD) conducted by the National Institute of Mental Health (NIMH), CERC-301 was well-tolerated and despite the small sample size, results suggested that an oral formulation of CERC-301 may have rapid antidepressant properties in TRD patients. The 135 patient, placebo-controlled Phase 2 study is designed with input from a panel of clinical experts in the treatment of depression to assess CERC-301 as adjunctive treatment. The study population consists of MDD subjects who would likely benefit most from rapid onset antidepressant activity - those who are failing current selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) treatment, have had recent active suicidal ideation, and are deemed appropriate for an out-patient study with careful safety surveillance. The safety and efficacy of CERC-301 will be evaluated over 28 days of treatment, and the primary endpoint is the change in the Hamilton Depression Rating Scale at day 7.
Similar Private Companies By Industry
Recent Private Companies Transactions